2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
July 2024 in “International Journal of Molecular Sciences” The inhibitor DPP can promote hair growth.
37 citations
,
May 2007 in “International Journal of Pharmaceutics” PPCM microspheres allow controlled finasteride release over 24 hours.
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
March 1998 in “Journal of dermatological science” Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
15 citations
,
April 2008 in “Steroids” The more lipophilic the progesterone derivative, the better it binds to androgen receptors and has antiandrogenic effects.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
17 citations
,
December 2015 in “Bioorganic & Medicinal Chemistry” 3-tetrazolo steroidal analogs can strongly inhibit the enzyme linked to hair loss.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
17 citations
,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
23 citations
,
July 2021 in “International Journal of Pharmaceutics” New dissolving and implantable microneedle patches have been created for a long-lasting, non-invasive delivery of the drug finasteride.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
January 2026 in “Biomaterials Science” The formulation helps improve wound healing and skin repair.
3 citations
,
October 1993 in “Endocrinology” 3 citations
,
April 2016 in “Research and reports in urology” The new saw palmetto extract effectively inhibits an enzyme linked to prostate enlargement and may be as good as standard treatments.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
December 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” A new combination of tadalafil and finasteride improves drug performance and stability.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
87 citations
,
July 2018 in “Biochimica et Biophysica Acta (BBA) - Molecular Cell Research” Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
August 2025 in “Frontiers in Pharmacology” [6]-Gingerdiol 3-monoacetate shows promise for treating T. whipplei infections.